{"entity":{"id":"de-escalate-iadt","kind":"trial","name":"DE-ESCALATE (EORTC trial of intermittent androgen deprivation with AR pathway inhibitors)","aka":["Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors","EORTC DE-ESCALATE"],"tldr":"A large European trial asking whether men with prostate cancer that has spread, who respond well to modern hormone treatment, can take planned breaks from it without shortening their lives, with fewer side effects and lower cost.","summary":"DE-ESCALATE is a Horizon Europe Cancer Mission project (CORDIS 101104574, topic HORIZON-MISS-2022-CANCER-01-03), coordinated by the EORTC in Brussels, running from 1 June 2023 to 31 May 2028 with an EU contribution of about EUR 7.2 million. Its CORDIS objective is to evaluate whether intermittent intensified androgen deprivation therapy in metastatic prostate cancer is not inferior to continuous treatment in oncological benefit while reducing side effects and resource use and improving quality of life, with a design meant to detect early any negative effect on overall survival; the consortium includes oncologists, surgeons, health economists and patient representatives.\n\nClinicalTrials.gov lists it as NCT05974774, \"Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors\", a phase 3 study sponsored by the EORTC in prostate cancer, recruiting, with an actual start on 23 May 2025 and a planned enrolment of 1,600.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov: NCT05974774","url":"https://clinicaltrials.gov/study/NCT05974774"},{"label":"CORDIS: DE-ESCALATE (101104574)","url":"https://cordis.europa.eu/project/id/101104574"}],"tags":[],"related":[],"cancers":["prostate-mhspc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":["eu-mission-on-cancer"],"pathways":[],"terms":["intermittent-androgen-deprivation","adt","de-escalation"],"trials":[],"people":[],"bottlenecks":["b-toxicity-qol","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Not the De-ESCALaTE HPV trial in head and neck cancer (record de-escalate), which shares the acronym; this record carries no bare \"DE-ESCALATE\" alias for that reason.","No results have been reported. The design label non-inferiority is the CORDIS objective's own framing."],"nct":"NCT05974774","phase":"3","design":"non-inferiority","setting":"Metastatic hormone-sensitive prostate cancer on intensified hormone therapy: intermittent versus continuous treatment","sponsor":"European Organisation for Research and Treatment of Cancer (EORTC)","started":"2025-05-23","startedType":"actual","enrolled":1600,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/de-escalate-iadt/","neighbours":{"cancer":[{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/"}],"institution":[{"id":"eu-mission-on-cancer","kind":"institution","name":"EU Mission on Cancer (Horizon Europe)","route":"/institutions/eu-mission-on-cancer/"}],"term":[{"id":"adt","kind":"term","name":"Androgen deprivation therapy (ADT)","route":"/terms/adt/"},{"id":"de-escalation","kind":"term","name":"De-escalation, escalation and response-adapted therapy","route":"/terms/de-escalation/"},{"id":"intermittent-androgen-deprivation","kind":"term","name":"Intermittent androgen deprivation (IAD)","route":"/terms/intermittent-androgen-deprivation/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}]}}